Knowledges

The BETMAT rFC assay combines a 30-minute assay time, 96-well format, 0.005–50 EU/mL linear range, and a simple one-step procedure, providing an efficient and streamlined workflow for routine and high-throughput endotoxin testing.

Advanced BET endotoxin analysis system with high-precision readers and pyrogen-free microplates for reliable quantitative testing.

BETMAT Kinetic Chromogenic LAL Reagent delivers accurate, compliant endotoxin testing for pharmaceutical and medical device applications.

Discover how BETMAT's recombinant cascade reagent (rCR) assay helps pharmaceutical manufacturers transition from traditional LAL testing to sustainable recombinant endotoxin testing with improved consistency, regulatory compliance, and reduced glucan interference.

Learn how kinetic chromogenic LAL reagents enhance quantitative endotoxin testing with higher sensitivity, regulatory compliance, and improved pharmaceutical quality control performance.

Discover BETMAT's advanced kinetic turbidimetric LAL reagent for quantitative endotoxin detection. USP <85> compliant, highly sensitive, reliable, and ideal for pharmaceutical quality control.

Bacterial endotoxin, a lipopolysaccharide component of the outer membrane of Gram-negative bacteria, poses significant risks to human health when present in injectable drugs, medical devices, and biological products. The Limulus Amebocyte Lysate (LAL) test has become the gold standard for endotoxin detection due to its high sensitivity, specificity, and rapidity.

On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued the second edition of the Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers, delivering updated, practice-oriented regulatory compliance direction for the pharmaceutical, biological product, and medical device industries.

In the bacterial endotoxin test using the gel clot Limulus Amebocyte Lysate (LAL) assay, the Maximum Valid Dilution (MVD)​ is a critical calculated parameter. Its importance is multifaceted.